An interventional study of ARISE Strategy in Diabetes Mellitus (Type 2) and Prediabetes, sponsored by epHealth. Not yet recruiting at 2 sites in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by epHealth · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 36 open to participants now, 45 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one has the largest planned enrollment of the 295 interventional ones that give a count, is one of 23 that started in 2026, is one of 82 with no phase, reaches primary completion later than 23 of the 44 other live ones, and was the 311th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →36 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Sao Francisco · Sites in Brazil
Ages 40–80 · Healthy volunteers
Eli Lilly and Company · Sites in Brazil, United States, China and 7 more countries
Ages 18+
AstraZeneca · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 7 more countries
Ages 10–18
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 151 · Phase 4 37
First in 2002; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45,000 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 326 across the 295 interventional studies, 370 across the 22 observational. Of the 239 that completed or were terminated, 116 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 317 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with epHealth as lead sponsor.
epHealth has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07463859University of Sao PauloEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus | 2027-01-31 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
| NCT06735859Federal University of São PauloEating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss | 2027-06 |
| NCT07846319epHealthEvaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at UBS (Primary Health Care Units) in Afogados da Ingazeira, during the 12 months post-implementation, compared to a reference value estimated from a historical 12-month period in the same municipality.
Methodology: Pragmatic, quasi-experimental, single-arm effectiveness and implementation study with a historical comparator. In each period, the analytic population will be defined by eligibility on the respective index date. In the historical period, data will estimate the reference proportion of the primary outcome and historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months via care records. Individuals who become eligible after the post-intervention index date may receive care actions under the strategy and be included in operational, implementation, and exploratory analyses, but not in outcome denominators fixed at the index date.
The study will take place in Afogados da Ingazeira, Pernambuco, covering all 15 UBS with an affiliated Family Health Team. Research-specific technological components will incur no additional cost to the municipality.
ARISE comprises two components:
A census-based approach will define population size. The primary analysis includes all individuals eligible on the post-intervention index date; final numbers depend on municipal database findings. Power calculations covered 8,000-30,000 eligible individuals and historical T2DM diagnosis proportions of 0.80%-0.90%. A population of \~14,000-15,000 eligible individuals yields \~80% power to detect a \~25% relative increase, for historical proportions of 0.85%-0.90%. For professional-related components, a census approach covers all eligible categories per the updated roster of active professionals directly involved.
Statistical analysis: The post-intervention proportion of confirmed T2DM diagnosis will be compared to the historical reference using a two-tailed one-proportion test (5% significance level). Point estimates, 95% CIs, absolute differences, and proportion ratios (where applicable) will be reported. Adjusted analyses may use logistic regression. Change in professionals' knowledge will be analyzed via paired intra-individual pre/post-training score differences. RE-AIM indicators will be mainly descriptive. Acceptability, training reaction, and workflow perception blocks will be scored separately (1-5). Usability will be assessed via the System Usability Scale (0-100) among professionals who directly used the digital component.
The study was approved by the Research Ethics Committee (REC), CAAE n. 00260026.5.0000.5330, approval opinion n. 8.705.723.
Primary outcome: Confirmed T2DM diagnosis during the observation period, treated as a binary individual indicator.
Background: Type 2 diabetes mellitus (T2DM) is a major cause of morbidity, disability, and premature mortality. A significant proportion of people with T2DM remain undiagnosed, and prediabetes is even less frequently identified. Although Primary Health Care has guidelines for screening, systematic identification of eligible individuals is hindered by data fragmentation, incomplete records, interoperability limitations, and the absence of mechanisms to operationalize the criteria of the Clinical Protocol and Therapeutic Guidelines for T2DM in teams' routine practice.
Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, according to the criteria defined in the protocol and based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at the UBS (Primary Health Care Units) of Afogados da Ingazeira, during the 12 months following implementation, compared to a reference value estimated from a historical 12-month period in the same municipality.
Methodology: This is a pragmatic, quasi-experimental, single-arm effectiveness and implementation study using a historical comparator. The following periods will be defined: a historical reference period, lasting 12 months; a preparation and implementation period, lasting up to 30 days; and a post-intervention period, lasting 12 months, beginning on the activation date of the digital analytics layer. In each period, the analytic population will be defined based on eligibility existing on the respective index date. In the historical period, data will be used to estimate the reference proportion of the primary outcome and the historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months through care records. Individuals who become eligible after the post-intervention index date may receive the care actions provided for in the strategy and be included in operational, implementation, and exploratory analyses, but will not be included in the denominators of outcomes whose population was fixed at the index date.
The study will be conducted in the municipality of Afogados da Ingazeira, Pernambuco, including the 15 Primary Health Care Units (UBS) with an affiliated Family Health Team. The municipality has an estimated population of 40,241 inhabitants and has used epHealth digital solutions integrated into Primary Health Care routine since 2018. The municipality's participation will be voluntary and formalized through a Technical Cooperation Agreement, which will establish the parties' responsibilities, the conditions for data access and processing, and the integration of the strategy into the municipal care routine. Implementation of the research-specific technological components will not incur any additional cost to the municipality.
The ARISE strategy will consist of two components:
A census-based approach will be used for population size. The primary analysis will include all individuals meeting eligibility criteria on the post-intervention index date. The final number will depend on the population actually identified as eligible in the municipal databases. Power calculations considered scenarios ranging from 8,000 to 30,000 eligible individuals and historical proportions of confirmed T2DM diagnosis between 0.80% and 0.90%. A population of approximately 14,000 to 15,000 eligible individuals provides power close to 80% to detect a relative increase of approximately 25%, in scenarios with a historical proportion between 0.85% and 0.90%. For the components involving professionals, a census-based approach will be used across eligible categories and roles, according to the updated list of professionals in active service who are directly involved in the strategy.
For the statistical analysis, the proportion of confirmed T2DM diagnosis observed in the post-intervention period will be compared to the historical reference proportion using a two-tailed one-proportion test, considering a 5% significance level. Point estimates, 95% confidence intervals, absolute differences, and, where applicable, proportion ratios will be presented. Adjusted analyses and assessments of associated factors may use logistic regression models. Change in professionals' knowledge will be analyzed in a paired manner, using the intra-individual difference between post- and pre-training scores. RE-AIM indicators will be evaluated predominantly in a descriptive manner. The blocks assessing acceptability, reaction to training, and perception of workflow will be analyzed separately, using scores from 1 to 5. Usability will be assessed using the System Usability Scale, with scores from 0 to 100, among professionals who directly used the digital component.
The intervention will last 12 months, preceded by a preparation and training period of up to 30 days. The historical reference period will also comprise 12 months. After the end of the post-intervention period, database consolidation, statistical analyses, report preparation, and scientific dissemination of results will be carried out.
The study was approved by the Research Ethics Committee (REC), under Certificate of Presentation for Ethical Consideration (CAAE) No. 00260026.5.0000.5330 and approval opinion No. 8.705.723.
Primary outcome: The primary outcome will be confirmed diagnosis of T2DM during the observation period, treated as a binary individual indicator. The numerator will consist of eligible individuals classified as screening-positive for T2DM according to the criteria defined in the protocol. The denominator will consist of all individuals eligible for screening on the index date of the post-intervention period. The post-intervention proportion will be compared to the historical reference value, estimated by applying the same eligibility rules and outcome definition to the historical data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: ARISE Strategy
This is a pragmatic, quasi-experimental, single-arm effectiveness and implementation study using a historical comparator. The ARISE strategy will consist of two components: (1) Digital analytics layer. The layer will use structured data extracted from the e-SUS PEC (Primary Care Information System) to apply predefined eligibility rules for T2DM screening. Identified individuals will be made available in operational lists and may generate alerts for UBS managers and community health agents and technicians. The alerts will support the organization of visits, contacts, scheduling, test requests, follow-up of pending items, and patients' return to the unit. No test, consultation, diagnosis, prescription, referral, or treatment will be carried out automatically. Clinical decision-making will remain the responsibility of professionals and managers. (2) Professional training: UBS managers, community health agents, community health agent technicians, physicians, nurses, and nursing technicians
Proportion of individuals with confirmed diagnosis of type 2 diabetes mellitus (T2DM)
Time frame: 12 months post-intervention (compared to a 12-month historical reference period)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 12 months is below that.
Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.